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Introduction
Low back pain affects nearly 75 % of the human population at some stage in their lives (Hohaus et al., 2008) . Consequently, low back pain is a serious socioeconomic burden: in the US, the total cost exceed $ 100 billion per year (Katz, 2006) . Degeneration of the intervertebral disc (IVD) has been associated with low back pain. The IVD arises from the embryonic notochord and mesenchyme and is situated between the vertebrae, where it transmits loads and allows stable multi-directional spinal mobility Risbud et al., 2010) . The healthy IVD consists of the annulus fibrosus (AF) and nucleus pulposus (NP). Degeneration of the IVD is a complex, multifactorial process that is characterised by changes in the cell phenotype and composition of the extracellular matrix. During IVD degeneration, the glycosaminoglycan (GAG, a proteoglycan side chain) and water content decreases in the NP, changing the biomechanical environment of the IVD cells. Because of the changed IVD matrix, diffusion of nutrients becomes impaired, which further deteriorates the health of the IVD cells and healthy matrix synthesis. Since the avascular IVD exhibits inadequate matrix repair, a vicious circle develops in which the IVD weakens and experiences increased vulnerability to damage by physiologic loading (Bergknut et al., 2013; Colombini et al., 2008) .
Current medical, physiotherapeutic and surgical treatments for IVD disease aim at reducing neurological deficits and pain, rather than IVD repair. For this reason, regenerative strategies like gene-, growth factor-or cellbased therapies, that try to repair the degenerated IVD biologically, have gained increasing interest (Bach et al., 2014; Gilbert et al., 2013) . They either aim at increasing the cell numbers by cell transplantation and/or by stimulating proliferation of the resident cells or matrix anabolism. Thus far, several growth factors and peptides (e.g. bone morphogenetic protein, Link N) have been shown to promote cell proliferation and/or matrix formation in vitro and/or in vivo in animal models with experimentally induced IVD degeneration (Chujo et al., 2006; Huang et al., 2007; Kwon et al., 2013; Masuda et al., 2006; Mwale et al., 2011) . In addition, cell-based treatments using mesenchymal stromal cells (MSCs), articular chondrocytes and chondrocyte-like cells (CLCs) derived from the NP (Gilbert et al., 2013; Henriksson et al., 2011; Yim et al., 2014) have been tested. To date, however, only a limited number of regenerative therapies have entered the clinical 133 www.ecmjournal.org FC Bach et al.
NCs of different species regenerate human CLCs phase as a treatment for human IVD degeneration (e.g. the Mesoblast study (allogeneic mesenchymal precursor cell (MPC) transplantation), http://clinicaltrials.gov/ show/:NCT00813813 (recombinant human growth and differentiation factor-5 (rhGDF-5)), NCT01640457 (NOVOCART ® disc plus autologous disc chondrocyte transplantation), NCT01771471 (allogenic juvenile chondrocytes (NuQu) transplantation), NCT01643681 (autologous adipose tissue derived MSC transplantation), NCT02338271 (autologous adipose tissue derived MSC transplantation), and the study by Mochida et al. (2015) : MSC-activated CLC transplantation). During IVD maturation, a transition in cell phenotype takes place from large, vacuolated notochordal cells (NCs) to smaller, non-vacuolated CLCs (Hunter et al., 2004; Purmessur et al., 2013b) . During this process, the vacuolated NCs obtain a transitional phenotype, i.e. they maintain their size but do not contain vacuoles. Thereafter, they obtain a morphology of rounded CLCs. Early NC loss in certain species (e.g. chondrodystrophic dogs) coincides with the onset of IVD degeneration. NC-conditioned medium (NCCM, containing factors secreted by NCs) and NC:CLC co-culture stimulate in vitro differentiation of MSCs into a NP-like phenotype Korecki et al., 2010; Purmessur et al., 2011) , protect the NP from apoptosis (Erwin et al., 2011; Mehrkens et al., 2013) , and/or increase CLC proliferation and GAG production (Abbott et al., 2012; Aguiar et al., 1999; Gantenbein et al., 2014; Potier et al., 2014) . In addition, NCs significantly stimulate CLC activity and GAG production (Gantenbein-Ritter et al., 2012) and produce more GAGs than CLCs (Saggese et al., 2014) . NCs have also been described to exert potential symptom modifying actions, e.g. anti-inflammatory, anti-neurogenic and antiangiogenic effects by secreting factors as sonic hedgehog, noggin, connective tissue growth factor and chondroitin sulphate (Cornejo et al., 2015; Gantenbein et al., 2014; Purmessur et al., 2013a) . Thus, NCs secrete factors with auspicious potential, making them an interesting target for regenerative and/or symptom modifying therapies (Bach et al., 2014) . NC-based regenerative strategies are being developed, using canine non-chondrodystrophic (NCD) and porcine donors because of easy availability of their NC-rich NP tissue (Bach et al., 2014) . Although regenerative effects of canine and porcine NC-secreted factors on human CLCs/MSCs have been demonstrated in several studies (Abbott et al., 2012; Korecki et al., 2010; Mehrkens et al., 2013; Purmessur et al., 2011) , the impact of human NC-secreted factors has never been determined, most probably due to limited availability of human NC-rich NP tissue. It is, however, important to define if the human CLC response to homologous human NC-secreted factors is superior to canine and porcine NC-secreted factors. Therefore, the main aim of this study was to delineate whether secreted factors from NC-rich NP tissue from different species have a differential regenerative effect on human CLCs derived from degenerated IVDs. For this purpose, human, canine and porcine NC-rich NP tissue was cultured to generate NCCM. Given the differences in life span and in NC-maintenance with ageing between these species, it impossible to account for the ageing effect and distinguish it from the species-specific NCCM effect. Human CLCs derived from degenerated IVDs (Thompson grade III) were isolated and after expansion cultured in human, canine or porcine NCCM using a micro-aggregate culture system and compared with CLCs cultured in basal and chondrogenic culture medium.
Materials and methods
NC-rich NP tissue sources IVD tissue (Thompson grade I) was collected from 12 human, 13 canine and 7 porcine donors. IVDs from human donors between 20 weeks of gestation and 3 months of age (postnatal) were obtained during a standard post mortem diagnostic procedure in which part of the spine was collected within 48 h after death, as approved by the scientific committee of the Pathology department of the University Medical Centre Utrecht. Anonymous use of redundant tissue for research purposes is a standard treatment agreement with patients in the University Medical Centre Utrecht (Local Medical Ethical Committee (METC) number 12-364). The material was used in line with the code 'Proper Secondary Use of Human Tissue' as installed by the Federation of Biomedical Scientific Societies. Complete canine spines (18-23 months of age) were collected from NCD dogs that had been euthanised in unrelated research studies (approved by the Utrecht University Animal Ethics Committee). Complete porcine spines (3 months of age) were collected from the slaughterhouse in accordance with local regulations. IVDs from all donors were opened under sterile conditions and NP tissue was collected by precise separation from the AF and cartilaginous endplates.
DNA and extracellular matrix content of human, canine and porcine NC-rich NP tissue
Collagen, DNA and GAG content NC-rich NPs from 4 human (22 weeks of gestation, 3 d, 5 d and 3 months of age), 21 canine (18-23 months of age) and 6 porcine (3 months of age) donors were used for histological and biochemical analysis. The human, canine and porcine NP tissue (naturally hydrated) was weighted using a microbalance. Papain digestion solution (pH 6, 200 mM H 2 NaPO 4 *2 H 2 O (21254, Boom B.V., Meppel, the Netherlands), 10 mM EDTA (100944, Merck Millipore, Amsterdam, the Netherlands), 10 mM cysteine HCl (C7880, Sigma-Aldrich, Saint Louis, USA), and 10 mM papain (P3125, Sigma-Aldrich, Saint Louis, USA) was added to each NP, followed by overnight incubation at 60 °C. The collagen content of NC-rich NP tissue was assessed using a hydroxyproline (HYP) assay (Neuman and Logan, 1950 
Collagen type I and II immunohistochemistry
For collagen type II immunohistochemistry (IHC), the sections were deparaffinised (see previously). Thereafter, they were blocked for 10 min with 0.3 % H 2 O 2 (51008600.9025, Boom B.V., Meppel, the Netherlands) and washed three times for 5 min with PBS + 0.1 %Tween (PBST0.1 %). Antigen retrieval was performed with 1 mg/ mL pronase (11459643001, Roche Diagnostics, Almere, the Netherlands) and 10 mg/mL hyaluronidase (H3506, Sigma-Aldrich, Saint Louis, USA) in PBS for 30 min at 37 °C. After washing with PBST0.1 %, the sections were blocked with 5 % BSA in PBS for 30 min at 37 °C. Thereafter, they were incubated overnight at 4 °C with collagen type II mouse monoclonal antibody (0.4 µg/ mL, II-II6B3, DSHB, Iowa City, IA) in 5 % BSA in PBS. In control staining, the first antibody was substituted with normal mouse IgG 1 (0.4 µg/mL; 3877, Santa Cruz Biotechnology, Heidelberg, Germany). These negative controls showed no aspecific positive staining. The next day, the sections were washed with PBST0.1 % before the secondary antibody (EnVision + System-HRP Goat Anti-Mouse, K4001, Dako, Glostrup, Denmark) was applied for 60 min at RT. After washing with PBS, the sections were incubated with the liquid DAB substrate chromogen system (K3468, Dako, Glostrup, Denmark) for 10 min and counterstained with haematoxylin QS solution (H3404, Vector Laboratories, Burlingame, USA) for 1 min. Thereafter, they were washed with tap water for 10 min and dehydrated with graded ethanol (70 %, 80 %, 96 % and 100 %) and xylene (two times 5 min) and mounted. For collagen type I IHC, the same procedures were followed with the Anti-Collagen I antibody (0.1 µg/mL, ab6308, Abcam, Cambridge, UK).
Generation and analysis of species-specific NCCM Generation of NCCM
Conditioned medium was generated from NC-rich NP tissue (Thompson grade I) of 10 human, 4 canine and 4 porcine donors ( Thereafter, the sections were incubated overnight at 4 °C with 1:50 diluted primary Collagen Type X antibody (2031501005, Quartett, Berlin, Germany). In control staining, the primary antibody was substituted with normal mouse IgG 1 (4 µg/mL; 3877, Santa Cruz Biotechnology, Heidelberg, Germany). These negative controls showed no aspecific positive staining. The next day, sections were washed with PBST0.1 % before the secondary antibody (EnVision+ System-HRP Goat Anti-Mouse, K4001, Dako, Glostrup, Denmark) was applied (30 min, RT). After washing with PBS, the sections were incubated with the liquid DAB substrate chromogen system, counterstained with haematoxylin QS solution, washed with tap water, dehydrated and mounted (see above).
Gene expression of the human CLC micro-aggregates
In order to study the transcriptional response of CLCs to NCCM at day 7, micro-aggregates (n = 6 per condition) were frozen in liquid nitrogen and crushed using pestles (P9951-901, Argos Technologies, Elgin, USA Primer uniqueness and specificity was determined using BLAST (Altschul et al., 1997) . Annealing temperatures were established by performing a temperature gradient PCR on a 16-fold dilution series. The four most stably expressed reference genes (TATAA-box binding protein (TBP), hypoxanthine-guanine phosphoribosyltransferase (HPRT), succinate dehydrogenase subunit A (SDHA) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ)) were chosen to normalise gene expression of the target genes (aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), Bcl2like-protein (BAX), B-cell CLL/lymphoma 2 (BCL-2), caspase-3 (CASP3), collagen type I (COL1A1), collagen type II (COL2A1), collagen type X (COL10A1), cyclin D1 (CCND1) and matrix metalloproteinase 13 (MMP13)). 
Results

Analysis of human, canine and porcine NC-rich NP tissue and species-specific NCCM
To characterise the species-specific NP tissue where the NCCM was generated from, the histological phenotype of the NC-rich NP tissue was determined. It appeared comparable in all human donors under 3 months. Healthy canine and porcine NP tissue contained considerably more typical large, vacuolated NCs than human NP tissue, which contained large areas of extracellular matrix with relatively few cells (Fig. 1) The GAG and DNA content per mg wet canine NCrich NP tissue was significantly higher than that of human and porcine NC-rich NP tissue ( Fig. 2a ; p < 0.05). The GAG content corrected for the DNA content of the human, canine and porcine NP tissue, however, was comparable for all species (data not shown). NC-rich human NP tissue contained significantly more collagen (per mg wet NP weight and per µg DNA of the NP) than NC-rich canine and porcine NP tissue ( Fig. 2b ; p < 0.05). In line with these results, the GAG/collagen ratio was significantly lower in the human than in the canine and porcine NC-rich NP ( Fig. 2c ; p < 0.05). Canine NC-rich NP tissue contained significantly more collagen per mg wet tissue than porcine NC-rich NP tissue (p < 0.01), but not more collagen per DNA content of the NP (Fig. 2b) . Additionally, there was no statistically significant difference in the GAG/collagen ratio between canine and porcine NC-rich NPs (Fig. 2c ). In the foetal human NP tissues, the GAG: collagen ratio was 3.4:1, which equals a GAG: hydroxyproline ratio of 25:1. The latter is in line with previous findings in healthy 2-to 5-year-old human donors, in which the NP GAG: hydroxyproline ratio was 25:1, whereas it was 2:1 in the AF and 3:1 in the cartilaginous endplate (Mwale et al., 2004) . Collagen type II protein was abundantly present in the extracellular matrix of the NP of all donors, regardless the donors species and age, whereas collagen type I was not expressed within the NP (Fig. 3) . Thus, in the present study, human NP tissue was successfully separated from AF tissue and that solely the effect of species-specific NPsecreted factors was compared, without interference from AF and/or endplate-secreted substances.
The protein and GAG concentration of human and porcine NCCM was comparable and significantly lower than that of canine NCCM (Fig. 2d ; p < 0.05). Collagen was undetectable in NCCM of all tested species (data not shown).
In vitro effects of species-specific NCCM on human CLCs derived from degenerated IVDs
Since NCCM contains a high GAG concentration that could attach to the outer layer of the micro-aggregates (resulting in an overestimation of the micro-aggregate GAG content), micro-aggregates were washed (1 min in 1 mL HBSS) to investigate whether this would result into a lower GAG content. Washing the micro-aggregates one or two times resulted into a significantly lower GAG/ DNA content (p < 0.05; Fig. 4 g) . There was no significant difference in GAG/DNA content between micro-aggregates that were washed two or three times.
No significant differences were detected in DNA, GAG and GAG/DNA content of micro-aggregates cultured in human NCCM generated under normoxic (NX) and hypoxic (HX) conditions (Fig. 4a-c ), suggesting that oxygen status during NCCM generation does not result into a differential biologic activity on human CLCs. Therefore, the results of these two NCCM conditions were pooled in the rest of the study. The DNA content of the human CLC micro-aggregates decreased over time in every culture condition, except for canine NCCM (p < 0.05; Fig. 4d ).
Although not as distinct as TGF-β 1 treatment, NCCM from all species significantly increased the DNA content of the micro-aggregates compared with controls (p < 0.001; Fig.  4d ). The DNA content of the micro-aggregates cultured in human NCCM was significantly lower than those cultured Fig. 4d ). NCCM from all species significantly increased the GAG and GAG/ DNA content of the micro-aggregates compared with untreated CLCs (p < 0.001; Fig. 4e and 4f) . Although not as potent as TGF-β 1 treatment, canine and porcine NCCM were significantly more potent than human NCCM in inducing GAG deposition by human CLCs (p < 0.001, Fig. 4e and 4f ). Safranin O/Fast Green staining indicated that GAGs were present in all NCCM-treated micro-aggregates ( Fig.  5) . A fibrotic rim that did not stain positive for GAGs was visible around the micro-aggregates treated with TGF-β 1 , canine and porcine NCCM, but was less prominent in human NCCM (Fig. 5 ). In line with these results, COL1A1 gene expression was significantly increased in these conditions compared with human NCCM and controls (p < 0.001; Fig. 6a ). Moreover, collagen type I protein was abundantly present in TGF-β 1 -treated micro-aggregates, and in lower amounts in canine and porcine NCCMtreated micro-aggregates (Fig. 6b ). The HYP assay was not sensitive enough to determine the collagen content of the micro-aggregates.
Although the micro-aggregates that were cultured in NCCM of all species demonstrated an increased GAG content (Fig. 4e) , ACAN and COL2A1 gene expression was not upregulated in these conditions compared with controls at day 7 (Fig. 6a ). While COL2A1 gene expression was significantly increased in the TGF-β 1 -treated microaggregates (p < 0.001; Fig. 6a ), only human NCCM-treated micro-aggregates contained some collagen type II protein (Fig. 6b ). Furthermore, no significant differences were encountered for gene expression of CCND1 (proliferation marker), ADAMTS5 (extracellular matrix degradation), CASP3 (apoptosis marker), BCL-2 (anti-apoptosis marker) and BAX (apoptosis marker) (data not shown). MMP13 (extracellular matrix degradation) gene expression was significantly upregulated in the TGF-β 1 -, porcine-, and human NCCM-treated micro-aggregates compared with controls (p < 0.05), whereas collagen type 10 (COL10A1, marker of hypertrophy) gene expression was only detected in the TGF-β 1 -treated micro-aggregates (data not shown). In contrast, collagen type X protein was not detected in the micro-aggregates treated with TGF-β 1 or NCCM regardless of the donor species (Fig. 6b) .
The GAG/DNA content of the micro-aggregates that were cultured in canine and porcine NCCM was significantly higher than those cultured in human NCCM (p < 0.001; Fig. 7a ). When the GAG/DNA content of the micro-aggregates was corrected for the DNA content (an indirect measure for cell number) of the NP tissue from which the NCCM was generated, porcine NCCM was more, and canine NCCM was less potent in increasing GAG deposition (p < 0.01, Fig. 7b ). Also when the GAG/ DNA content of the micro-aggregates was corrected for the protein and GAG concentration of species-specific NCCM, porcine NCCM was significantly more potent than human and canine NCCM (p < 0.01, Fig. 7c and 7d) . Fig. 6 . Both canine and porcine NC-conditioned medium (NCCM) induces collagen type I production, whereas only human NCCM induces collagen type II production in human chondrocyte-like cells (CLCs) derived from degenerated intervertebral discs (IVDs). Extracellular matrix production of human CLCs derived from degenerated IVDs cultured in micro-aggregates in basal culture medium (control), chondrogenic culture medium (with 10 ng/mL TGF-β 1 ) and NCCM of different species. (a) Relative ACAN, COL2A1 and COL1A1 gene expression (mean ± SD) of the micro-aggregates at day 7. The control micro-aggregates were set at 1. n = 6 per condition. a: p < 0.05; b: p < 0.01; c: p < 0.001. (b) Immunohistochemical staining for collagen type I, II and X at day 28. Human: human NCCM (NX and HX samples pooled); Canine: canine NCCM (HX); Porcine: Porcine NCCM (HX).
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Discussion
Differential deposition of extracellular matrix by species-specific NCCM Canine and porcine NC-secreted factors have already shown promising potential for IVD regeneration (Abbott et al., 2012; Gantenbein et al., 2014; Korecki et al., 2010; Mehrkens et al., 2013; Purmessur et al., 2011) . The impact of human NC-secreted factors and the differential effects of xenogeneic NCCM on human CLCs, however, have never been investigated. The present study was, to our knowledge, the first to test the regenerative potential of human NCCM. Furthermore, this study sought to identify whether NC-secreted factors of different species exerted a differential regenerative effect on human CLCs derived from degenerated IVDs. This study demonstrates a crossspecies effect of bioactive NC-secreted factors on human CLCs derived from degenerated IVDs. NCCM of all species, generated under identical conditions on the basis of wet NP weight, increased CLC cell numbers and GAG deposition, but canine and porcine NCCM appeared more potent than human NCCM. Although the IVD is an avascular hypoxic structure and several studies have demonstrated that NCs respond superior to hypoxic than normoxic culture conditions (Erwin et al., 2009; Omlor et al., 2014) , no difference in regenerative potential was found between human NCCM generated under HX or NX conditions. Unpublished work by our group indicates that also no difference in biologic activity was established between canine NCCM that was generated under NX or HX conditions. In agreement with our studies, previous work demonstrating the regenerative potential of porcine and canine NC-secreted factors have used NCCM generated under HX (Abbott et al., 2012; Purmessur et al., 2011) and NX (Aguiar et al., 1999; Boyd et al., 2004; Erwin et al., 2011; Korecki et al., 2010) conditions. Altogether, this may imply that oxygen status during NCCM generation does not result in a differential biologic activity of NC-secreted factors on human CLCs. Matrix deposition by the degenerated CLCs could have been transcriptionally induced, but we cannot exclude the possibility that GAGs from the NCCM were incorporated in the deposited CLC matrix. Although increased GAG deposition was encountered in all NCCM-treated microaggregates and, albeit limited, collagen type II deposition was present in the human NCCM-treated micro-aggregates at day 28, gene expression of ACAN and COL2A1 was not upregulated at day 7. In line with our findings, expression of extracellular matrix-related genes is also not increased in porcine NCCM-treated cultures at day 2 (porcine CLCs) (Boyd et al., 2004) , 7 (human CLCs) (Abbott et al., 2012) and 28 (bovine CLCs) . In contrast, an increased expression of extracellular matrix-related genes is encountered in canine NCCM-treated bovine CLCs after 1 d and canine CLCs after 28 d of treatment . Human MSCs treated with porcine NCCM also demonstrate an increased expression of extracellular matrix-related genes at day 21 (Purmessur et al., 2011) . In the above-mentioned studies, different cell types (CLC or MSC) and different species for cell culture/ NCCM generation were used. In addition, NCCM was generated in different ways (culture medium, additives, days of generation, whole NP tissue or NCs), and the cells were cultured using different systems and/or conditions, which hampers the comparison of results. Altogether, NCCM achieves regenerative effects by transcriptional regulation of anabolic matrix genes and we may have missed this time-window at 7 d of NCCM culture.
TGF-β 1 treatment induced undesirable fibrotic (re) differentiation of the CLCs, confirmed by a fibrotic rim around the micro-aggregates and increased collagen type I deposition, while even after 28 d of culture there was no evident collagen type II deposition. NCCM exerted a species-specific anabolic effect on human CLCs derived from degenerated IVDs. While porcine and canine NCCM were more potent in inducing GAG and collagen type I matrix deposition, only human NCCM induced collagen type II deposition. These differences imply that not only quantitative but also qualitative differences in bioactive factors may be present in human compared with canine or porcine NCCM. In addition, the bioactive substances in NCCM may be present in a suboptimal concentration. Therefore, future work should aim at the identification of GAG and collagen type II inducing factors in human, canine and porcine NCCM. Combinatory strategies with an optimal balance between bioactive NC-secreted factors may induce optimal NP matrix production. Moreover, the identified species-specific NC-secreted factors may also improve articular cartilage repair, in which GAG and collagen type II production is desirable.
Species-specific NP properties may influence the observed regenerative capacity of NCCM
In this study, phenotypical and biochemical differences between species of NP tissue and NCCM were established, which may account for the observed differential regenerative potency of species-specific NCCM. Numerous typical large, vacuolated NCs were encountered in all canine and porcine NPs (Hunter et al., 2003; Hunter et al., 2004; Smolders et al., 2013) , but in very limited numbers in human NPs. Humans lose their NCs at about 6-10 years of age (Hunter et al., 2004) , but in the present study, NCs were only scarcely present in foetal NPs. Only few cells with mainly a transitional or CLC phenotype were present in foetal human NP tissue, indicating that the NCs gradually obtained a mature phenotype (Purmessur et al., 2013b) . Previous studies also reported mixed NC: CLC populations in foetal human NPs (Rutges et al., 2010; Shen et al., 2013) . Specific conditions (e.g. hyperglycaemia) have been shown to cause premature NC apoptosis (Won et al., 2009 ). In the present study, human NC-rich NPs were obtained from non-viable individuals with specific disorders and/or anomalies, which may have influenced the health of the NP tissue and the presence of NCs within these NPs together with the gestation age of the donors. Inherently, the limited presence of NCs may have affected the regenerative potential of human NCCM in this study.
Overall, canine and porcine NCCM were equally potent and more potent than human NCCM in inducing CLC matrix production. However, when taking into account the cellularity (DNA content) of the NP tissue from which the NCCM was generated or the NCCM protein or NCCM GAG concentration, porcine NCCM appeared more potent than canine NCCM. The latter may have been influenced by the differences in lifespan and age (canine: 18-23 months, porcine: 3 months) of the donor species, which may translate into a differential regenerative effect related to NC-physiology. Hence, porcine NCCM may have exerted a relatively more potent regenerative effect than canine NCCM because of the young age of the porcine donors. Since all species have a different life span and lose their NCs at different ages, it would have been a challenge to find 'comparable' interspecies donors. Thus, it is impossible to distinguish species from aging effects of the NCCM. The ageing effect could be circumvented by employing healthy prenatal tissues at a species-specific developmental stage immediately after the development of the IVD. Nevertheless, from a practical point of view, canine and porcine NC-rich NP tissue is more easily available than human NC-rich NP tissue and both exerted a significant regenerative effect on human CLCs. Therefore, canine and in particular porcine donors are suitable for the development of NC-based technologies, in which the NC-secreted bioactive factors can be identified, isolated and eventually synthesised in a human recombinant form.
Limitations of the study
The first limitation of this study is that passage 2 (P2) CLCs were used. Cell expansion for one or more passages likely induced dedifferentiation of the CLCs, a wellknown phenomenon for articular chondrocytes (Bekkers et al., 2014; Veilleux et al., 2004) . Since dedifferentiated CLCs could respond differently from freshly isolated CLCs (P0), future studies should determine the effect of (species-specific) NCCM on P0 CLCs and explants. In order to overcome the sample volume limitations of the human NCCM (about 1 mL human NCCM was generated per donor), CLCs derived from IVDs with Thompson grade III from three human donors were pooled in order to assess a representative degenerated CLC population. For this reason, the regenerative effect of species-specific 144 www.ecmjournal.org FC Bach et al.
NCs of different species regenerate human CLCs NCCM was also not tested on CLCs derived from human IVDs with other degeneration grades or on CLCs derived from other species. Furthermore, the human CLC microaggregates were cultured under normoxic conditions. CLCs may respond more pronounced to the bioactive NCsecreted factors under hypoxic than normoxic conditions given the hypoxic nature of the NP (Feng et al., 2013; Yang et al., 2013) . Therefore, further research under hypoxic conditions is necessary to confirm the obtained results with CLCs from several donors with different IVD degeneration grades. Lastly, it remains to be elucidated if other (symptom modifying) markers were affected by NCCM treatment than the ones measured in the present study, e.g. anti-inflammatory/neurogenic/angiogenic markers (Purmessur et al., 2013a) .
Clinical relevance
The present study showed that human, canine and porcine NC-secreted factors exerted regenerative effects on human CLCs isolated from degenerated IVDs. Future studies should concentrate on how NCs communicate with CLCs and which (species-specific) NC-secreted factors induce the regenerative effects. Once the bioactive NC-secreted factors have been identified and isolated, synthetic human recombinant products can be developed and their safety and efficacy can be determined. Since canine and porcine NC-secreted factors have a considerable regenerative potential and NC-rich NP tissue from these species is more easily available than human NC-rich NP tissue, canine or porcine NC-based regenerative treatments with synthetic human recombinant products have a promising potential for successful translation into humans.
Conclusions
This study demonstrated a cross-species effect of human, canine and porcine NC-secreted factors. NCCM derived from all these species exerted regenerative effects on human CLCs derived from degenerated IVDs in terms of GAG deposition and cell numbers. No difference in regenerative potential was found between human NCCM generated under hypoxic or normoxic conditions. The qualitative and quantitative differences in species-specific NP tissue and NCCM resulted in a differential regenerative effect on human CLCs. Given that canine and porcine NCrich NP tissue is more easily available than human NC-rich NP tissue and that both canine and porcine NC-secreted factors exerted regenerative effects on human CLCs, canine and in particular porcine donors are suitable to delineate the underlying bioactive substances resulting into IVD regeneration. Once the canine/porcine bioactive NCsecreted factors have been identified and isolated, synthetic human recombinant products can be developed and tested in vitro and in vivo. Combinatory strategies with an optimal balance between species-specific bioactive NC-secreted factors may further improve healthy NP matrix production.
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